Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORUS-Cytomegalovirus Proof-of-concept Exploratory Trial
2025-524845-28-00Phase 4Authorised
- Sponsor
- Lausanne University Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of everolimus in cytomegalovirus disease (CMV) (2 arms), sponsored by Lausanne University Hospital. Primary endpoint: Change in CMV Viral Load. Planned start Aug 2026; status: authorised.
02
Drugs
everolimus
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2025-524845-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524845-28-00.